Search results
Results From The WOW.Com Content Network
Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. [8]In 1995, the Patel and Modi families split; the Modi family's share was moved into a new company called Cadila Pharmaceuticals, and Cadila Healthcare became the Patel family's holding company.
Cadila Pharmaceuticals is an Indian multinational pharmaceutical company based in Ahmedabad. The company's operations focus on manufacturing products ranging from active pharmaceutical intermediates , finished formulations , food supplements, biotechnology products and pharmaceutical machinery.
Zydus Wellness (previously Carnation Nutra-Analogue Foods) is an Indian consumer goods company headquartered in Ahmedabad, which produces nutrition and skincare products. It is a subsidiary of the pharmaceutical company Zydus Lifesciences (formerly known as Cadila Healthcare).
The state is home to several large pharmaceutical companies: Sun Pharmaceuticals,Cadila Pharmaceuticals, Torrent Pharmaceuticals, Alembic Pharmaceuticals, Intas Pharmaceuticals, Zydus Lifesciences, Amneal Pharmaceuticals, USV Pharmaceuticals, Baxter Healthcare and Outsuka Pharma more. [5] [6]
Indravadan Ambalal Modi (18 February 1926 – 26 November 2012) [1] was an Indian pharmaceuticals industrialist who founded Cadila Pharmaceuticals in Ahmedabad.He is popularly known as the 'Medicine Man of India' for his contribution to the pharmaceutical industry of India post independence.
He took charge in 1995 after a formal separation between the two founding families from Zydus Cadila to Zydus Lifesciences and Cadila Healthcare. [7] When he took over the Cadila Healthcare, he was faced with two challenges: His was a Rs 200-crore company whereas his overheads including management, research, company expenses, and staff worked ...
In 2014, Indian drugmaker Cadila Healthcare declared the launch of the first adalimumab biosimilar at a fifth of its US price. The generic was launched under the brand name Exemptia. [96] In 2016, Indian drugmaker Torrent Pharmaceuticals launched its biosimilar for adalimumab, called Adfrar. It is the second generic biosimilar of adalimumab.
A study called The Indian Polycap Study (TIPS) was sponsored by Cadila Pharmaceuticals Limited, (where the drug development program was coordinated by JP Parswani, President, and Dr. Arun Maseeh, Vice-President Medical Affairs), and led by Dr. Salim Yusuf of McMaster University in Hamilton, Ontario, and Dr. Prem Pais of St. John's Medical College in Bangalore, India.